Analysis of IgG Profile Serum from Different SARS-Cov2 Post-Vaccination Periods

The quantification of the antibody response to SARS-CoV-2 vaccination is considered relevant for identifying possible vaccine failure and estimating protection time. Various types of vaccines have been produced to suppress the development of SARS-Cov2 from numerous approaches, starting from the use of inactivated whole viruses, genetic material (mRNA), and transmembrane proteins (spike protein-RDB). The strategy to increase herd immunity to SARS-cov2 infection through the vaccination program is estimated to impact health significantly. The presence of post-vaccination antibodies (IgG) needs to be monitored to determine the effectiveness of vaccines that have been immunized on a person, how long the protective power is produced from vaccinations that a person receives so that other vaccination programs can be confirmedly determined to obtain herd immunity and eliminate transmission of COVID-19 nationally. This study aimed to study the polyclonal character of the antibody induced by the specific protein from post-vaccinated patients. In this study, we also determined the highest antibody titer among groups using the ELISA method. According to SDS-PAGE visualization, we found a specific band, a 158 kDa, found explicitly in post-vaccine groups only. This protein will be selected as a protein antigen to produce rabbit polyclonal antibodies for further study. Based on the results of the polyclonal antibody production, it can be concluded that a 158 kDa protein isolate can stimulate a humoral immune response by a polyclonal antibody with the highest antibody titer detected at fifth-week blood collection. The selected polyclonal antibody specificity test was able to identify protein isolates from post-vaccinated patient's serum with a molecular weight of 158 kDa.